About Martin Glen

This author has not yet filled in any details.
So far Martin Glen has created 17 entries.

17 April 2019

Cytora – Secures £25m Series B for its AI-powered insurance underwriting solution

By |April 17th, 2019|

Portfolio company Cytora, that has developed an AI-powered solution for commercial insurance underwriting, has raised £25 million in a Series B round. New investor EQT Ventures led the round with Parkwalk, Cambridge Innovation Capital and a number of others investors participating.
A spin-out of the University of Cambridge, Cytora  was founded in 2014 and launched its first product in […]

25 February 2019

Petmedix – Parkwalk’s latest investment

By |February 25th, 2019|

Parkwalk are delighted to announces its investment in Petmedix. The Cambridge based pet therapeutics company raises £8M Series A funding, with Parkwalk co-investing alongside Digitalis Ventures. Parkwalk were attracted by the team and the market potential.

PetMedix is applying 30 years of antibody research and the scientific work of two of its founders, Professor Allan Bradley […]

10 January 2019

Flusso – Opportunities and UCEF V & VI investment

By |January 10th, 2019|

We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Funds V and VI, managed by Parkwalk, have participated in the first major financing round of Flusso, the University of Cambridge spin-out which has developed an innovative high-performance gas flow sensor.

Flusso is a 2018 spin-out from the High […]

Cytora and QBE expand its relationship to enhance data-driven business insurance

By |January 2nd, 2019|

Following a successful pilot project, QBE has begun using Cytora’s Risk Engine technology to enhance underwriting decisions across its commercial portfolio.
The Cytora Risk Engine learns the patterns of good and bad risks over time, combining the digital footprint of every business with insurers’ internal data to generate a comprehensive risk profile and score for […]

4 December 2018

Ceres Power and Weichai finalise strategic collaboration and JV Agreement

By |December 4th, 2018|

Ceres Power (AIM: CWR, “Ceres”), a world-leading, low cost Solid Oxide Fuel Cell company, and Weichai Power (“Weichai”), one of the leading automobile and equipment manufacturing companies in China, are pleased to announce the finalisation of their long-term strategic collaboration first announced in May 2018. This includes a Joint Venture Agreement with the commitment […]

20 October 2018

DefiniGEN – Parkwalk closes follow on investment

By |October 20th, 2018|

Parkwalk closes DefiniGen investment.

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production platform OptiDIFF robustly generates human cell types including using hIPSC human […]

Congenica – earns major role in supporting world’s first routine national genomic medicine service

By |October 17th, 2018|

Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service

Cambridge, United Kingdom – 17 October, 2018 – Congenica has been awarded a multi-year contract by Genomics England, to be a provider of Diagnostic Decision Support Services for them to deliver for the world leading NHS Genomic […]

17 September 2018

Exonate – University of Bristol Enterprise Fund II investment

By |September 17th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Exonate.

Exonate are developing a novel approach to modulating new vessel growth.  By controlling the balance of two contrasting forms of a protein called Vascular Endothelial Growth Factor (VEGF), they have demonstrated that they could not only treat models […]

30 July 2018

AQDOT – Follow on Investment

By |July 30th, 2018|

We have recently made a follow-on investment into Aqdot on behalf of the Parkwalk Opportunities EIS Fund.

Aqdot is a spin-out from the Department of Chemistry at the University of Cambridge and was founded in late 2012. Its proprietary technology introduces an innovative, simple method for manufacturing structures in the millimetre and nanometre range that are […]

PervasID – Parkwalk and UCEV V investment

By |July 20th, 2018|

We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund V, managed by Parkwalk, have invested in PervasID, a spin-out from the Department of Engineering.

The company has developed a long-range passive Radio-Frequency Identification (RFID) tracking technology which substantially outperforms current passive RFID technologies. Crucially, it allows low-cost […]

16 May 2018

Ceres Power – announces strategic partnership with China’s Weichai Power

By |May 16th, 2018|

Parkwalk portfolio company Ceres Power Holdings plc (AIM: CWR) has announced a strategic collaboration with China’s Weichai Power (“Weichai”) comprising both product development and launch as well as a potential initial £17.0m equity investment by Weichai in Ceres Power.

The long term strategic relationship provides Ceres Power with access to the Chinese market, the world’s fastest growing […]

3 April 2018

Parkwalk closes Boxarr investment

By |April 3rd, 2018|

We are pleased to announce that the Parkwalk Opportunities Fund and University of Bristol Enterprise Fund I have made an investment in Boxarr, who provide analytical and data visualisation support to solve highly complex supply chain, systems, process and project business problems.

The company has developed a unique, versatile tool and powerful methodology that is unparalleled […]

28 March 2018

Oxford Endovascular – Parkwalk and UOIF IV investment

By |March 28th, 2018|

We have recently closed an investment in Oxford Endovascular for the Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV.

Oxford Endovascular have developed Oxiflow, a novel, next generation ‘flow-diverter’ that diverts blood flow away from intracranial aneurysms at risk of rupture. The device is a metallic mesh tube, laser cut from Nitinol […]

20 February 2018

OxSyBio – Parkwalk closes Investment

By |February 20th, 2018|

We are delighted to announce that Parkwalk has participated in the funding of OxSyBio, which is seeking to commercialise IP generated by Professor Hagan Bayley at the University of Oxford.

The company has the unique ability to 3D print materials that have function derived from biology, but which are not living. The company is also able to print […]

Cytora – Parkwalk closes follow-on Investment

By |February 6th, 2018|

The University of Cambridge Enterprise Fund V and the Parkwalk Opportunities Fund  have closed an investment into Cytora, an artificial intelligence risk analytics spin-out from the University of Cambridge.

Cytora  raised $5.9 million in new financing from investors including divisions of QBE’s venture capital arm and Starr Cos.

QBE Ventures, Starr Global Holding, Cambridge Innovation Capital, Cambridge […]

9 January 2018

Ilika plc – Half-year report

By |January 9th, 2018|

Ilika (AIM: IKA), a pioneer in solid-state battery technology and materials innovation, announces its unaudited half yearly report for the six months ended 31 October 2017.
Operational Highlights
·     Exchanged detailed Stereax® performance data with over 60 potential OEM partners
·     Shipped sample batteries to 10 potential OEM partners for detailed technical evaluation
·     Three of these have progressed to development […]

28 November 2017

Parkwalk closes Opsydia investment

By |November 28th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund has made an investment in Opsydia, a spin-out company from the Department of Engineering Science at the University of Oxford, specialising in designing bespoke optical systems and laser fabrication processes for complex and unique ideas.